Liu Z, Wang Q, Yang D, Mao K, Wu G, Wei X
Mol Genet Metab Rep. 2024; 40:101102.
PMID: 38911695
PMC: 11190550.
DOI: 10.1016/j.ymgmr.2024.101102.
Peng Y, Pan M, Wang Y, Shen Z, Xu J, Xiong F
Ren Fail. 2024; 46(2):2362391.
PMID: 38847497
PMC: 11164125.
DOI: 10.1080/0886022X.2024.2362391.
Furia A, Ditaranto R, Biagini E, Parisi V, Incensi A, Parisini S
BMC Neurol. 2024; 24(1):113.
PMID: 38580906
PMC: 10996216.
DOI: 10.1186/s12883-024-03540-3.
Breyer M, Gruner J, Klein A, Finke L, Klug K, Sauer M
Mol Genet Metab Rep. 2024; 38:101029.
PMID: 38469097
PMC: 10926200.
DOI: 10.1016/j.ymgmr.2023.101029.
Kermond-Marino A, Weng A, Xi Zhang S, Tran Z, Huang M, Savige J
Kidney Int Rep. 2023; 8(7):1373-1379.
PMID: 37441486
PMC: 10334396.
DOI: 10.1016/j.ekir.2023.04.009.
High-expression of Galactosidase alpha is correlated with poor prognosis and immune infiltration in low-grade glioma.
Zhang Y, Li J, Yin X
J Cancer. 2023; 14(4):646-656.
PMID: 37057282
PMC: 10088540.
DOI: 10.7150/jca.81975.
Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
Modrego A, Amaranto M, Godino A, Mendoza R, Barra J, Corchero J
Int J Mol Sci. 2021; 22(12).
PMID: 34204583
PMC: 8234732.
DOI: 10.3390/ijms22126518.
Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants.
Encarnacao M, Coutinho M, Silva L, Ribeiro D, Ouesleti S, Campos T
Int J Mol Sci. 2020; 21(17).
PMID: 32883051
PMC: 7503609.
DOI: 10.3390/ijms21176355.
Functional evaluation of a novel GLA causative mutation in Fabry disease.
Li P, Zhang L, Xiong Q, Wang Z, Cui X, Zhou Y
Mol Genet Genomic Med. 2019; 7(9):e864.
PMID: 31321922
PMC: 6732343.
DOI: 10.1002/mgg3.864.
Fabry Disease with Pacemaker Implantation as the Initial Event.
Kato Y, Ishikawa A, Aoki S, Sato H, Ojima Y, Kagaya S
Intern Med. 2019; 58(20):2993-3000.
PMID: 31243236
PMC: 6859394.
DOI: 10.2169/internalmedicine.2468-18.
Three unrelated protease inhibitors enhance accumulation of pharmaceutical recombinant proteins in Nicotiana benthamiana.
Grosse-Holz F, Madeira L, Zahid M, Songer M, Kourelis J, Fesenko M
Plant Biotechnol J. 2018; 16(10):1797-1810.
PMID: 29509983
PMC: 6131417.
DOI: 10.1111/pbi.12916.
Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.
Wu Y, Xia H, Yuan J, Xu H, Deng X, Liu J
Curr Genomics. 2018; 19(1):70-75.
PMID: 29491734
PMC: 5817879.
DOI: 10.2174/1389202918666170915155033.
Predicting the Effect of Single and Multiple Mutations on Protein Structural Stability.
Dehghanpoor R, Ricks E, Hursh K, Gunderson S, Farhoodi R, Haspel N
Molecules. 2018; 23(2).
PMID: 29382060
PMC: 6017198.
DOI: 10.3390/molecules23020251.
α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K
J Biol Chem. 2012; 287(34):28386-97.
PMID: 22773828
PMC: 3436532.
DOI: 10.1074/jbc.M112.351056.
The molecular basis of pharmacological chaperoning in human α-galactosidase.
Guce A, Clark N, Rogich J, Garman S
Chem Biol. 2011; 18(12):1521-6.
PMID: 22195554
PMC: 3246215.
DOI: 10.1016/j.chembiol.2011.10.012.
A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.
Wu X, Katz E, Valle M, Mascioli K, Flanagan J, Castelli J
Hum Mutat. 2011; 32(8):965-77.
PMID: 21598360
PMC: 3170878.
DOI: 10.1002/humu.21530.
Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
Park J, Kim G, Kim S, Ko J, Lee J, Yoo H
Exp Mol Med. 2009; 41(1):1-7.
PMID: 19287194
PMC: 2679280.
DOI: 10.3858/emm.2009.41.1.001.
Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
Shin S, Kluepfel-Stahl S, Cooney A, Kaneski C, Quirk J, Schiffmann R
Pharmacogenet Genomics. 2008; 18(9):773-80.
PMID: 18698230
PMC: 2657085.
DOI: 10.1097/FPC.0b013e32830500f4.
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.
Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A
Nat Biotechnol. 2008; 26(8):901-8.
PMID: 18688246
PMC: 3478093.
DOI: 10.1038/nbt.1484.
Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
Ishii S, Chang H, Kawasaki K, Yasuda K, Wu H, Garman S
Biochem J. 2007; 406(2):285-95.
PMID: 17555407
PMC: 1948963.
DOI: 10.1042/BJ20070479.